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TO THE EDITOR
Chromosomal translocations involving the immunoglobulin heavy
chain (IGH) locus at chromosome 14q32 represent a frequent event
in multiple myeloma (MM). We and others have identified a new
recurring t(4;14)(p16.3;q32) chromosomal translocation, which
involves the most telomeric region of chromosome 4 in which the
FGFR3 gene (a member of the tyrosine-kinase receptor family FGFR1–
4) and the novel gene WHSC1/MMSET (a putative transcription factor)
are located.1–3
Otsuki et al4 have recently characterized the KMS-18 cell line estab-
lished from an MM patient, which shows several numerical and struc-
tural chromosomal abnormalities including a putative, non-karyotyp-
ically detectable t(4;14)(p16.3;q32) that may involve the FGFR3 locus.
In order to characterize this lesion further, we performed a FISH analy-
sis as we previously described.5 Using painting probes specific for
chromosomes 4 and 14, we detected two apparently normal chromo-
somes 4 (data not shown) and two unidentified chromosomes bearing
sequences from chromosome 14 (Figure 1a1). One of the structurally
altered chromosomes was recognized by the probes specific for the
Ca region of the IGH locus and the FGFR3 locus (cosmid clone 7.1),
which colocalized in its telomeric region (Figure 1a2). In addition,
the clone 7.1 recognized one of the two apparently normal chromo-
somes 4 (Figure 1a2). Finally, co-hybridization with the JH region and
the cosmid A1 specific for the 39 region of the MMSET locus revealed
associated signals on the putative der(4) (Figure 1a3). These data indi-
cate that the t(4;14)(p16.3;q32) in the KMS-18 cell line leads to a
complex chromosomal rearrangement, and that the 4p16.3 break-
point is located between MMSET and FGFR3 loci.
Molecular analyses of the 4p16.3 breakpoints cloned so far indicate
that they are dispersed 50–100 kb centromeric to the FGFR3 gene
and within the 59 regions of the MMSET gene (Figure 2a).1–3 In order
to characterize the KMS-18 breakpoints at molecular level, we perfor-
med a Southern blot analysis based on our previously described
assay.1 Using probes specific for the IGH constant and joining regions,
two non-comigrating rearranged DNA fragments were identified by
JH and Cg probes (Figure 1b). Since our attempt to clone the Cg frag-
ment was unsuccessful (probably because of the length of the
fragment), we isolated the JH-rearranged DNA fragment. The restric-
tion map and sequence analysis shown in Figure 1c indicate that the
4p16.3 breakpoint is located within intron 3 of the MMSET gene 402
bp upstream of exon 4,6 and therefore involves the same region as
that containing previously cloned breakpoints (Figure 2a).
The t(4;14) translocation leads to the overexpression of the FGFR3
gene, as well as to the generation of IGH-MMSET hybrid transcripts,
the presence of which has been proposed as a molecular marker for
the translocation.3,7 In the KMS-18 cell line we detected the
expression of FGFR3 gene as recently reported by Nakazawa et al,8
and the presence of IGH-MMSET hybrid transcripts that lack exons
1–3 of the MMSET gene as expected from the MB4–2 type breakpoint
(Figure 2b and c).7 These data support the hypothesis that the two
genes play a role in myelomagenesis.
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Figure 1 Cloning of the t(4;14)(p16.3;q32) chromosomal breakpoint in the KMS-18 MM cell line. (a) FISH analyses of the KMS-18 cell line;
panels 1, 2 and 3 show partial KMS-18 metaphases hybridized with the probes specified below. The cosmid clones 7.1 (FGFR3) and A.1
(MMSET) were isolated from a human placenta cosmid library (Clontech, Palo Alto, CA, USA) using as probes FGFR3 cDNA and a PCR-
generated fragment located about 60 kb centromeric to the 39 end of the MMSET gene. DAPI counterstaining is shown for each chromosome.
(b) Southern blot analysis: DNAs from KMS-18 line cell and placenta (control) were digested with the BamHI restriction enzyme and hybridized
first with the JH and then with the Cg probe; aberrant DNA fragments are indicated by arrows, and the molecular weight marker is indicated
in kilobases (kb). (c) Schematic representation of the cloned t(4;14)(p16.3;q32) breakpoint. Diagram of the phage clone that contains the aberrant
rearranged fragment on der(4) chromosome: chromosome 14 sequences are indicated by a white box with the switch (S) and joining (JH) regions
specified by green boxes; the chromosome 4 regions are shown as a solid line with red boxes representing exons 4, 5 and 6 of the MMSET
gene. The position of the breakpoint between exon 3 and 4 of the MMSET gene is indicated by a vertical arrow; the restriction enzymes HindIII
(H) and BamHI (B) are shown. Below is the nucleotide sequence analysis of the breakpoint region in the KMS-18 cell line and its alignment
with the corresponding 4p16.3 germline one. The typical IGH switch repeat sequences are underlined.
Figure 2 (a) Schematic representation of the cloned 4p16.3 MM breakpoints (indicated by arrows).1–3 (b) RT-PCR analysis of FGFR3 expression
in MM cell lines using primers UF2 59-TGGAGTTCCACTGCAAGGTGTA-39 and TD3 59-GGAGATCTTGTGCACGGGTGG-39;1 the length of the
FGFR3 amplified fragment is indicated in bp. The U266 MM cell line was used as a negative control; case LB-2100 has been previously
described.7 (c) RT-PCR detection of the IGH-MMSET hybrid transcripts using primers Im2 and ms6r as in the previously described assay;7 the
length of the amplified fragments is indicated in bp (the one at the top contains the putative exon 4a).
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